The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells

Overview of attention for article published in Leukemia, February 2009

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (78th percentile)
Above-average Attention Score compared to outputs of the same age and source (52nd percentile)

Mentioned by

patent: 4 patents

Citations

dimensions_citation: 281 Dimensions

Readers on

mendeley: 199 Mendeley

Summary Patents Dimensions citations

So far, Altmetric has seen 4 patents that reference this research output.

Biomarkers for predicting responsiveness to decitabine therapy

Grant US-11793825-B2

United States of America

Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and…

Grant US-10973773-B2

United States of America

Biomarkers for predicting responsiveness to decitabine therapy

Grant US-10940160-B2

United States of America

METHODS FOR PREDICTING MULTIPLE MYELOMA TREATMENT RESPONSE

Application WO-2014044848-A1

World Intellectual Property Organisation (WIPO)